On August 11th, 2022, the Food and Drug Administration (FDA) approved Enhertu (fam- trastuzumab deruxtecan-nxki) for treatment of advanced non-small cell lung cancer (NSCLC) with an activating HER2 mutation for patients who have received one prior line of therapy. [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]
GO2 for Lung Cancer team pictured: Joelle Fathi, DNP, RN, ARNP, FAAN; Daniel Saez, MSc; Jennifer C. King, PhD By Jennifer C. King, PhD, Chief Scientific Officer and Daniel Saez, MSc, Manager, LungMATCH Navigation Program The [...]
Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment options targeting mutations that were previously unavailable for [...]
Stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated in recent years by the genetic mutation, or biomarker. Patients received either chemotherapy, immunotherapy, a combination of the two, or a personalized targeted therapy depending on the [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer Surgery has been the primary treatment for early stage non-small cell lung cancer (NSCLC). Unfortunately, many people have seen their cancer come back after surgery. Now researchers [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung Cancer and Daniel A. Saez, MSc, Navigator, Treatment & Trials, GO2 for Lung CancerNew Hope for Patients with KRASUntil recently, the KRAS mutation was considered un-targetable in most types [...]
By Rashmi Acharya, MS; Andrew Ciupek, PhD; Jennifer C. King, PhD; and Daniel Saez, MSc The annual meeting held by the American Society of Clinical Oncology (ASCO) is the stage for presenting many of the most impactful advancements in cancer research – including in lung cancer. Health equity was the major theme of the 2021 meeting, held June 4-8, 2021, and multiple [...]
By Daniel A. Saez, M.Sc., Treatment and Trials Navigator, GO2 for Lung Cancer In today’s lung cancer care landscape, biomarker testing has become a crucial part of the treatment decision for many oncologists. Targeted therapies can be more effective [...]
By Andrew Ciupek, Ph.D., Manager, Clinical Research, GO2 for Lung Cancer Approximately 30% of Non-Small Cell Lung Cancers (NSCLC) have an EGFR mutation. For these patients EGFR targeted therapy has greatly increased survival. Tagrisso (osimertinib) has become the drug [...]